Advertiser / Brand · vs · B2C Consumer App & Plattform
Haleon vs Hims & Hers
Strukturierter Technologie- und Marktvergleich · Stand 2026
Direkte Merkmalsgegenüberstellung
Haleon · vs · Hims & HersBörsennotiertes Consumer-Healthcare-Unternehmen mit Fokus auf die alltägliche Gesundheit.
Konsumenten-Telemedizinplattform mit abonnementbasierter Behandlung und pharmazeutischer Distribution.
Vergleichsanalyse & Key Insights
Was ist der Hauptunterschied zwischen Haleon und Hims & Hers?
Beim Vergleich von Haleon und Hims & Hers agieren beide Plattformen im Bereich Advertiser / Brand und B2C Consumer App & Plattform. Haleon ist positioniert als Börsennotiertes Consumer-Healthcare-Unternehmen mit Fokus auf die alltägliche Gesundheit, während Hims & Hers den Schwerpunkt auf Konsumenten-Telemedizinplattform mit abonnementbasierter Behandlung und pharmazeutischer Distribution legt. Beide Anbieter stellen komplementäre wie auch konkurrierende Kernfähigkeiten für den Markt bereit.
Welche Alternativen gibt es zu Haleon und Hims & Hers?
Bei der Evaluierung von Haleon und Hims & Hers prüfen Enterprise-Entscheider häufig auch weitere Plattformen im Bereich Advertiser / Brand und B2C Consumer App & Plattform. Die erweiterte Wettbewerbslandschaft und detaillierte Marktprofile findest du direkt auf Polaris7.
Echtzeit-Beobachtung
Aktuelle Marktsignale & News: Haleon vs Hims & Hers
Öffentlich erfasste Marktbewegungen, Partnerschaften, Produkt-Updates und strategische Ankündigungen aus dem Knowledge-Graphen.
Haleon
Letzte Aktivitäten
Aktuell keine kürzlichen Signale im Erfassungszeitraum für Haleon dokumentiert.
Hims & Hers
Letzte Aktivitäten
- ·PR Newswire: Technology NewsPrivacy
Hims & Hers Securities Fraud Class Action Filed
A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) in the U.S. District Court for the Northern District of California. The suit alleges the telehealth company failed to disclose that it shared sensitive health information with third-party advertising platforms, including Snap and Meta (Facebook), and misled consumers about its billing practices, including premature prescription charges. The FTC filed a related lawsuit on July 29, 2026, prompting a 14.73% stock decline to $25.00. Investors who purchased HIMS securities between August 4, 2025, and July 29, 2026, have until November 2, 2026, to apply as lead plaintiff. The case, Velanki v. Hims & Hers Health, Inc. et al., is being publicized by law firms including Kahn Swick & Foti, Kessler Topaz Meltzer & Check, and the Law Offices of Howard G. Smith.
- FTC sued Hims & Hers for sharing sensitive health data with advertising platforms and deceptive billing practices.
- Hims & Hers stock dropped $4.32 (14.73%) to $25.00 on July 29, 2026.
- Class action lawsuit filed; lead plaintiff deadline is November 2, 2026.
- ·Modern RetailProduct Design / D2C Pharmaceutical Convergence
Hims & Hers' Prescription Gummy Drives High Adherence
Hims & Hers launched a prescription Biotin + Minoxidil gummy for hair growth in June 2025. One year after launch the company surveyed 300 customers and reported an 88% daily adherence rate; 79% cited the green apple flavor as a reason for continued use and about two-thirds said the frosted glass jar packaging improved their experience. The article describes manufacturing and formulation challenges in creating a prescription-grade gummy and notes Hims & Hers' broader strategy of using design to de-stigmatize prescription products. The company reported $608.1 million in Q1 revenue in its May earnings report and gave full-year guidance of $2.8 billion to $3 billion.
- Hims & Hers launched the Biotin + Minoxidil Gummy (prescription) in June 2025.
- Hims & Hers surveyed 300 customers and reported an 88% daily adherence rate for the gummy.
- 79% of surveyed customers said the green apple flavor was a key reason they kept taking the gummy; nearly two-thirds said the frosted glass jar packaging made the experience more positive.
- ·techcrunchPrivacy
FTC sues Hims & Hers over sharing health data
The U.S. Federal Trade Commission has sued telehealth and consumer healthcare company Hims & Hers, alleging the company shared customers’ sensitive medical and healthcare information with advertisers and major tech firms including Meta and Snap, and misled consumers about its privacy practices. The FTC's complaint, filed in a California federal court, says Hims & Hers placed pixel-sized trackers from Meta, Snap, Microsoft, Pinterest, Reddit and X that captured and shared users’ health information. The complaint also accuses the company of deceptive billing practices and creating barriers to cancellation. Hims & Hers responded that its privacy policy enables users to choose how their data is used and said it will defend against the allegations. The action continues a pattern of FTC enforcement against healthcare-related companies over third-party web trackers.
- The Federal Trade Commission filed a lawsuit accusing Hims & Hers of sharing customers’ medical and healthcare information with advertisers and tech companies, including Meta and Snap.
- The FTC alleged Hims & Hers placed pixel-sized trackers provided by Meta, Snap, Microsoft, Pinterest, Reddit, and X that captured and shared users’ health information.
- The FTC also accused Hims & Hers of deceptive billing and designing policies that made it difficult for customers to cancel, in violation of federal consumer protection laws.
Exakte Ökosystem-Überschneidungen vergleichen
Erkunde alle tiefen Marktbeziehungen in Polaris7. Entdecke gemeinsame Kunden, integrierte Technologien, SDK-Schnittstellen und überlappende Partner von Haleon und Hims & Hers im Markt-Ökosystem.